-
2024-511885-35-00
5
2019-07-03
macular telangiectasia type 1
-
2023-503673-38-00
5
2019-05-24
Adults at high risk of cardiovascular events without prior MI or strok
-
2022-500797-34-00
4
2018-12-17
Treatment of participants with positive cancer for HRRm or HRD.
-
2023-510426-33-00
5
2018-09-27
Moderately to Severely Active Crohn's Disease
-
2023-508083-30-00
4
2018-07-19
Non-small cell lung cancer (NSCLC)
-
2023-504038-23-00
9
2018-05-10
Metastatic non-small cell lung cancer (NSCLC)
-
2024-514586-20-01
5
2018-05-02
Non small cell lung cancer
-
2024-516783-29-00
6
2018-04-16
Severe allergic and eosinophilic asthma
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2024-515000-39-00
9
2017-01-17
Recurrent glioblastoma.
-
2022-500400-22-00
5
2016-06-23
Hodgkin lymphoma
-
2023-509360-24-00
5
2016-06-16
Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
-
2024-516750-21-00
9
2015-10-14
Patients with relapsed / refractory Mantle Cell Lymphoma
-
2023-509352-34-00
4
2015-06-18
Mantle Cell Lymphoma
-
2024-517856-36-00
5
2015-03-09
Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
-
2023-507291-52-00
4
2014-03-24
Extranodal Marginal Zone Lymphoma
-
2023-503807-27-00
4
Biliary tract carcinoma
-
2023-507207-66-00
5
Diabetic Macular Edema (DME)
-
2023-507344-36-01
4
Advanced or Metastatic Cancer
Merkel Cell Carcinoma (MCC)
Cutaneous Sq
-
2023-508684-68-00
9
Advanced solid tumor
-
2023-509227-41-00
4
Low risk of disease recurrence, defined by the following criteria:
- A
-
2024-512754-16-01
5
Prostate cancer
-
2024-514078-29-00
4
gastric and gastro-oesophageal junction adenocarcinomas
-
2024-515393-27-00
4
Nonsquamous non-small cell lung cancer